Table 4.
Problems associated with clozapine treatment
| Agranulocytosis | Cardiac issues | Blood monitoring | Diabetes mellitus | Weight gain | Drowsiness | Hypersalivation | Rebound psychosis | Dizziness | Nausea | Constipation | Other | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients vs. healthcare professionals | ||||||||||||
| PQ4 (n=100) | 7 (7.0) | 13 (13.0) | 31 (31.0) | 5 (5.0) | 24 (24.0) | 51 (51.0) | 76 (76.0) | 17 (17.0) | 28 (28.0) | 26 (26.0) | 41 (41.0) | 28 (28.0) |
| HPQ4 (n=104) | 98 (94.2) | 49 (47.1) | 65 (62.5) | 49 (47.1) | 23 (22.1) | 31 (29.8) | 41 (39.4) | 17 (16.3) | 4 (3.8) | 17 (16.3) | 20 (19.2) | 9 (8.7) |
| PQ5 (n=100) | 35 (35.0) | 36 (36.0) | 35 (35.0) | 36 (36.0) | 38 (38.0) | 51 (51.0) | 63 (63.0) | 47 (47.0) | 36 (36.0) | 29 (29.0) | 44 (44.0) | 20 (20.0) |
| HPQ5 (n=104) | 40 (38.5) | 17 (16.3) | 42 (40.4) | 18 (17.3) | 40 (38.5) | 43 (41.3) | 54 (51.9) | 16 (15.4) | 11 (10.6) | 22 (21.2) | 29 (27.9) | 5 (4.8) |
| Experienced vs. inexperienced | ||||||||||||
| Experienced | 56 (98.2) | 27 (47.7) | 39 (68.4) | 26 (45.6) | 13 (22.8) | 21 (36.8) | 31 (54.4) | 10 (17.5) | 2 (3.5) | 12 (21.1) | 17 (29.8) | 5 (8.8) |
| HPQ4 (n=57) | ||||||||||||
| Inexperienced | 42 (89.4) | 22 (46.8) | 26 (55.3) | 23 (48.9) | 10 (21.3) | 10 (21.3) | 10 (21.3) | 7 (14.9) | 2 (4.3) | 5 (10.6) | 3 (6.4) | 4 (8.5) |
| HPQ4 (n=47) | ||||||||||||
| Experienced | 17 (29.8) | 6 (10.5) | 28 (49.1) | 10 (17.5) | 22 (38.6) | 28 (49.1) | 38 (66.7) | 5 (8.8) | 4 (7.0) | 13 (22.8) | 18 (31.6) | 2 (3.5) |
| HPQ5 (n=57) | ||||||||||||
| Inexperienced | 23 (48.9) | 11 (23.4) | 14 (29.8) | 8 (17.0) | 18 (38.3) | 15 (31.9) | 16 (34.0) | 11 (23.4) | 7 (14.9) | 9 (19.1) | 11 (23.4) | 3 (6.4) |
| HPQ5 (n=47) | ||||||||||||
Values are presented as number (%).
PQ, patient questionnaire; HPQ, healthcare professionals questionnaire.